Clinical Trial Update: Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

This document notes a Phase 2 neoadjuvant trial investigating trastuzumab deruxtecan (SHR-A1811) in combination with pertuzumab for HER2-positive breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Perjeta (pertuzumab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: HER2 + Breast Cancer | Phase 2 | Status: RECRUITING